Medicine and Dentistry
Patient
90%
Vascular Disease
68%
Niacin
50%
Laropiprant
50%
Anacetrapib
50%
Inpatient
50%
Low Density Lipoprotein Cholesterol
46%
High Density Lipoprotein Cholesterol
37%
Adverse Event
28%
Statin
28%
Incidence
23%
Combination Therapy
22%
Diabetes
12%
Adult
11%
Myocardial Infarction
11%
Follow up
11%
Death
11%
Cardiovascular System
10%
Revascularization
6%
Diagnosis
6%
Infection
6%
Skin
6%
Musculoskeletal System
6%
Gastrointestinal System
6%
Aptitude
6%
Apoplexy
6%
Laboratory
6%
Heart Muscle Revascularization
5%
Cancer Mortality
5%
CETP Inhibitor
5%
Atorvastatin
5%
Cholesterol Ester Transfer Protein
5%
Therapeutic Procedure
5%
Amaurosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Vascular Disease
68%
Nicotinic Acid
50%
Low Density Lipoprotein Cholesterol
46%
High Density Lipoprotein Cholesterol
37%
Adverse Event
28%
Incidence
23%
Statin (Protein)
22%
Diabetes Mellitus
12%
Death
11%
Heart Infarction
11%
Infection
6%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
6%
Cancer Mortality
5%
Atorvastatin
5%
Blindness
5%
